What You Should Know:
– MAUI Imaging, inventor of patented Computed Echo Tomography (CET) technology that visualizes anatomy other ultrasound technologies cannot secures $14M in a Series D round led by Acertara Acoustic Laboratories and is allocated to support the production, sales, and marketing of the company’s innovative imaging technology.
– MAUI Imaging emerged from stealth in August 2024 with the announcement of a $4M U.S. Department of Defense (US Army Medical Research and Development Command) contract. This contract supports trauma medicine across four branches of the military, aiming to enable faster diagnosis and interventional care in high-volume or mass-casualty events and resource-limited environments. The program is being implemented at the University of Maryland Shock Trauma Center in Baltimore, a major trauma center where the military trains healthcare providers.
Computed Echo Tomography: Beyond Traditional Ultrasound Limitations
MAUI Imaging has developed a novel and effective approach to diagnostic imaging, resulting in a cross between ultrasound and CT without the need for dangerous ionizing radiation (x-rays). MAUI’s CET “pings” the designated part of the human body, uniquely visualizing anatomy beyond what other ultrasound systems can produce. It then uses proprietary patented algorithms to accommodate the reflected energy from various flight paths and sums the data to create a reliable image of all the structures below the probe. Barriers such as bone, gas, fat, instruments, and implants become part of the image instead of obstacles to image formation.
MAUI’s core patents address speed-of-sound aberration issues in tissue, enabling views of various tissue types, including lung and cranium, previously thought to be unobtainable. Its portfolio includes more than 160 granted patents and dozens more pending in and outside the U.S.
The MAUI approach requires trillions of calculations per second, which would not have been possible in a portable, cost-effective solution without advances in chip technology (often described as Moore’s Law). The system also creates significantly larger datasets that can be sliced into as many images as necessary, more akin to CT than traditional ultrasound. These datasets can be used for deeper analytics, providing more insight into the anatomy scanned, and MAUI’s volumetric imaging has the potential to significantly expand the role of ultrasound in AI-driven diagnostics.
MAUI K3900 FDA Clearance
The MAUI K3900 device received its 510(k) FDA clearance in October 2023 and is now available for commercial use. The MAUI K3900 Ultrasound Imaging System is intended for use by qualified healthcare personnel for ultrasound evaluation across a wide range of applications, including Fetal, Abdominal, Cardiac, Musculo-skeletal, Urology, and Intraoperative uses. Examples of differentiating images for use in trauma, neurosurgery, and interventional radiology can be found at .
Levi Moore, President and CEO of Acertara Acoustic Labs, commented, “The MAUI ultrasound system represents a major advancement in medical imaging. By reducing the complexity of image acquisition and offering an intuitive approach, it expands ultrasound’s reach to new users and clinical settings. We’re working closely with MAUI to accelerate adoption in hospitals nationwide, where this technology has the potential to save lives and significantly improve patient outcomes.”
MAUI Imaging is currently delivering devices to initial users, with Acertara leading pre-orders as the exclusive U.S. distributorship for hospitals outside those MAUI Imaging serves directly.
